Xeligekimab(GR1501)治疗中重度斑块状银屑病的多中心随机双盲安慰剂对照III期研究
该III期研究纳入420例中国中重度斑块状银屑病患者,随机接受xeligekimab 200mg每2周或安慰剂治疗12周,后延长为每4周至52周。第12周xeligekimab组PASI 75、90、100应答率分别为90.7%、74.4%、30.2%,显著高于安慰剂组,且疗效维持至第52周,安全性良好。
要点
- 第12周xeligekimab组PASI 75达90.7%,安慰剂组仅8.6%。
- PASI 75和PGA 0/1应答维持至第52周。
- 未记录到非预期不良事件,安全性与其他抗IL-17A单抗类似。
核心结论
- Xeligekimab在中国中重度斑块状银屑病患者中显示出高疗效且耐受性良好。
研究设计与样本
- 多中心随机双盲安慰剂对照III期研究,共纳入420例中国中重度斑块状银屑病患者,随机分为xeligekimab 200mg每2周组(n=281)和安慰剂组(n=139),治疗12周后延长为xeligekimab每4周至52周。
主要发现
- 第12周,xeligekimab组PASI 75、PASI 90、PASI 100应答率分别为90.7%、74.4%、30.2%,安慰剂组分别为8.6%、1.4%、0%。
- 第12周,xeligekimab组PGA 0/1应答率为74.4%,安慰剂组为3.6%。
- PASI 75和PGA 0/1应答维持至第52周。
- 未记录到非预期不良事件。
关键数值与推荐
- 第12周xeligekimab组PASI 75为90.7%,PASI 90为74.4%,PASI 100为30.2%,PGA 0/1为74.4%。
- 第12周安慰剂组PASI 75为8.6%,PASI 90为1.4%,PASI 100为0%,PGA 0/1为3.6%。
临床怎么用
- Xeligekimab可作为中国中重度斑块状银屑病的有效治疗选择,200mg每2周诱导后每4周维持可维持长期应答。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Xeligekimab (GR1501) is a fully human monoclonal antibody that selectively neutralizes interleukin (IL)-17A and has shown potential efficacy in treating moderate-to-severe psoriasis in preliminary trials. OBJECTIVES: To evaluate the efficacy and safety of xeligekimab in Chinese patients with moderate-to-severe psoriasis. METHODS: A total of 420 Chinese patients were randomized to 200 mg xeligekimab every 2 weeks (n = 281) or placebo (n = 139) for the first 12 weeks, followed by an extension of the treatment schedule to xeligekimab every 4 weeks for a further 40 weeks. Efficacy was assessed by evaluating achievement of Physician Global Assessment (PGA) 0/1 and 75%, 90% and 100% improvement in Psoriasis Area and Severity Index (PASI 75, PASI 90 and PASI 100, respectively). The safety profile was also evaluated. RESULTS: At week 12, PASI 75, PASI 90 and PASI 100 were achieved in 90.7%, 74.4% and 30.2% of patients in the xeligekimab group vs. 8.6%, 1.4% and 0% of patients in the placebo group, respectively. PGA 0/1 was achieved in 74.4% patients in the xeligekimab group and 3.6% of patients in the placebo group. PASI 75 and PGA 0/1 were maintained until week 52. No unexpected adverse events were recorded. CONCLUSIONS: Xeligekimab showed high efficacy and was well tolerated in Chinese patients with moderate-to-severe plaque psoriasis. Psoriasis is a skin disease characterized by scaly and raised patches of skin on any part of the body. The condition can be caused by a combination of how a person’s immune system works, their genes and their environment. A cytokine is a substance secreted by certain cells of the immune system that have an effect on other cells. One such cytokine, called IL-17A, has been associated with different inflammatory diseases, including psoriasis. We conducted a large trial in Chinese people with moderate-to-severe psoriasis to look at the efficacy (ability to produce the intended result) and safety of a medicine called xeligekimab (known as a ‘monoclonal antibody’) which works by targeting IL-17A. We randomly assigned 420 Chinese patients to receive 200 mg of xeligekimab every 2 weeks or a ‘placebo’ (no active medicine) for the first 12 weeks. We extended the treatment schedule of xeligekimab to every 4 weeks for a further 40 weeks. To assess how the medicine worked, we measured people’s psoriasis symptoms and severity. To assess how safe the medicine was, we looked at the side-effects (or ‘adverse events’). The results of this trial showed that xeligekimab improved people’s psoriasis and itching starting at week 4 of receiving treatment, and more than 60% of people achieved improvement or remission by week 6, which was sustained up to week 52. The safety of xeligekimab was similar to another medicine classed as a monoclonal antibody (called secukinumab) and there were no new or unexpected adverse events reported. Overall, our findings suggest that xeligekimab is a safe and effective medicine for the treatment of psoriasis in Chinese people.
引用
- Cai L, Jiang C, Zhang G, et al. A multicentre randomized double-blind placebo-controlled phase III study of the efficacy and safety of xeligekimab (GR1501) in patients with moderate-to-severe plaque psoriasis. Br J Dermatol. 2024. PMID: 38366639. doi:10.1093/bjd/ljae062
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。